{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:48Z","timestamp":1790207748521,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG ZH 1023 (FOR 5806)"],"award-info":[{"award-number":["DFG ZH 1023 (FOR 5806)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["project number 413490537"],"award-info":[{"award-number":["project number 413490537"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Faculty Mannheim","award":["Clinician Scientist program"],"award-info":[{"award-number":["Clinician Scientist program"]}]},{"name":"Medical Faculty of Christian Albrecht University"},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113858"],"award-info":[{"award-number":["70113858"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010441","name":"Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","award":["Clinician Scientist program"],"award-info":[{"award-number":["Clinician Scientist program"]}],"id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Access funding enabled and organized by Projekt DEAL."},{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01211-6","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:34:29Z","timestamp":1776706469000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-0159","authenticated-orcid":false,"given":"Lena","family":"Dreikhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Olkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Heumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Atanasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Letsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Wandmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzuo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/NRGASTRO.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380. https:\/\/doi.org\/10.1038\/NRGASTRO.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/S00268-007-9001-Y","volume":"31","author":"S Hasegawa","year":"2007","unstructured":"Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256\u201363. https:\/\/doi.org\/10.1007\/S00268-007-9001-Y.","journal-title":"World J Surg"},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/CNCR.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, Klimstra D, D\u2019Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689\u2013700. https:\/\/doi.org\/10.1002\/CNCR.11699.","journal-title":"Cancer"},{"key":"1211_CR4","doi-asserted-by":"publisher","DOI":"10.3892\/MI.2025.214","volume":"5","author":"JY Lee","year":"2025","unstructured":"Lee JY, Kim JW. Recent 5-year trends in biliary tract cancer survival rates: an analytical big data survey. Med Int. 2025;5:15. https:\/\/doi.org\/10.3892\/MI.2025.214.","journal-title":"Med Int"},{"key":"1211_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDOA2200015.","journal-title":"NEJM Evid"},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"1211_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100910","volume":"42","author":"C Kumar-Sinha","year":"2023","unstructured":"Kumar-Sinha C, Vats P, Tran N, Robinson DR, Gunchick V, Wu YM, et al. Genomics driven precision oncology in advanced biliary tract cancer improves survival. Neoplasia. 2023;42:100910. https:\/\/doi.org\/10.1016\/j.neo.2023.100910.","journal-title":"Neoplasia"},{"key":"1211_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/S41392-024-02097-4","volume":"10","author":"T Zhan","year":"2025","unstructured":"Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M, et al. Digestive cancers: mechanisms, therapeutics and management. Signal Transduct Target Ther. 2025;10:24. https:\/\/doi.org\/10.1038\/S41392-024-02097-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(20)30321-1.","journal-title":"Lancet Oncol"},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/JGO.2019.03.10","volume":"10","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10:751\u201365. https:\/\/doi.org\/10.21037\/JGO.2019.03.10.","journal-title":"J Gastrointest Oncol"},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/S11523-023-01002-3","volume":"18","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Ivosidenib: a review in advanced cholangiocarcinoma. Target Oncol. 2023;18:973\u201380. https:\/\/doi.org\/10.1007\/S11523-023-01002-3.","journal-title":"Target Oncol"},{"key":"1211_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/NATURE13441","volume":"513","author":"SK Saha","year":"2014","unstructured":"Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513:110\u201352. https:\/\/doi.org\/10.1038\/NATURE13441.","journal-title":"Nature"},{"key":"1211_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12113310","volume":"12","author":"M Salati","year":"2020","unstructured":"Salati M, Caputo F, Baldessari C, Galassi B, Grossi F, Dominici M, et al. IDH signalling pathway in cholangiocarcinoma: from biological rationale to therapeutic targeting. Cancers (Basel). 2020;12:1\u201311. https:\/\/doi.org\/10.3390\/CANCERS12113310.","journal-title":"Cancers (Basel)."},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1.","journal-title":"Lancet Oncol"},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/JAMAONCOL.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.3836.","journal-title":"JAMA Oncol"},{"key":"1211_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/LIV.70295","volume":"45","author":"M Niger","year":"2025","unstructured":"Niger M, Rimini M, Castet F, Melzer A, Rizzato MD, Pressiani T, et al. Ivosidenib for IDH1-mutant intrahepatic cholangiocarcinoma: insights from a multicenter real-world study. Liver Int. 2025;45:e70295. https:\/\/doi.org\/10.1111\/LIV.70295.","journal-title":"Liver Int"},{"key":"1211_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2025.7797","volume":"8","author":"M Najafzadeh","year":"2025","unstructured":"Najafzadeh M, Fern\u00e1ndez Oromendia A, Burcu M, Mcconnochie B, Kim E, Vaccaro T, et al. Linkage of clinical trial data to routinely collected data sources: a scoping review. JAMA Netw Open. 2025;8:e257797. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.7797.","journal-title":"JAMA Netw Open"},{"key":"1211_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/S13104-022-06243-5","volume":"15","author":"D Kiernan","year":"2022","unstructured":"Kiernan D, Carton T, Toh S, Phua J, Zirkle M, Louzao D, et al. Establishing a framework for privacy-preserving record linkage among electronic health record and administrative claims databases within PCORnet\u00ae, the National Patient-Centered Clinical Research Network. BMC Res Notes. 2022;15:337. https:\/\/doi.org\/10.1186\/S13104-022-06243-5.","journal-title":"BMC Res Notes"},{"key":"1211_CR20","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/FPHAR.2025.1516126","volume":"16","author":"RJ Ludwig","year":"2025","unstructured":"Ludwig RJ, Anson M, Zirpel H, Thaci D, Olbrich H, Bieber K, et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol. 2025;16:1516126. https:\/\/doi.org\/10.3389\/FPHAR.2025.1516126.","journal-title":"Front Pharmacol"},{"key":"1211_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/JAMIAOPEN\/OOAD035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6:ooad035. https:\/\/doi.org\/10.1093\/JAMIAOPEN\/OOAD035.","journal-title":"JAMIA Open"},{"key":"1211_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00067","volume":"2","author":"U Topaloglu","year":"2018","unstructured":"Topaloglu U, Palchuk MB. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inform. 2018;2:1\u201310. https:\/\/doi.org\/10.1200\/CCI.17.00067.","journal-title":"JCO Clin Cancer Inform."},{"key":"1211_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/JAMASURG.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565\u201374. https:\/\/doi.org\/10.1001\/JAMASURG.2013.5137.","journal-title":"JAMA Surg"},{"key":"1211_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/S12876-016-0527-Z","volume":"16","author":"KJ Yao","year":"2016","unstructured":"Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16:117. https:\/\/doi.org\/10.1186\/S12876-016-0527-Z.","journal-title":"BMC Gastroenterol"},{"issue":"16_Suppl.","key":"1211_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.E16227","volume":"43","author":"C Chen","year":"2025","unstructured":"Chen C, Han N, Chen A, Liu X, Chu X. Real-world survival outcomes with Ivosidenib in Chinese patients with IDH1-mutated intrahepatic cholangiocarcinoma. J Clin Oncol. 2025;43(16_Suppl.):E16227. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_SUPPL.E16227.","journal-title":"J Clin Oncol"},{"issue":"16_Suppl.","key":"1211_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.4086","volume":"43","author":"KI Zhou","year":"2025","unstructured":"Zhou KI, Baidya RN, Lin C, Scobie MR, McSkimming D, Kelley MJ, et al. Real world efficacy and safety of Ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma. J Clin Oncol. 2025;43(16_Suppl.):4086. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_SUPPL.4086.","journal-title":"J Clin Oncol"},{"key":"1211_CR27","doi-asserted-by":"publisher","DOI":"10.5603\/OCP.104900","author":"BA Cybulska-Stopa","year":"2025","unstructured":"Cybulska-Stopa BA, Cybulska-Stopa BJ, Kawecki M, Szyma\u0144ska P, Duszy\u0144ski P, Borysiewicz Z, et al. Ivosidenib in treatment of patients with cholangiocarcinoma with IDH1 mutation: real-world data from a multicenter study. Oncol Clin Pract. 2025. https:\/\/doi.org\/10.5603\/OCP.104900.","journal-title":"Oncol Clin Pract"},{"issue":"16_Suppl.","key":"1211_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.TPS4219","volume":"43","author":"JJ Harding","year":"2025","unstructured":"Harding JJ, El-Khoueiry A, Ueno M, Chon HJ, Kim JW, Choi HJ, et al. A phase 1b\/2, safety lead-in and dose-expansion trial of Ivosidenib plus Durvalumab and Gemcitabine\/Cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. J Clin Oncol. 2025;43(16_Suppl.):TPS4219. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_SUPPL.TPS4219.","journal-title":"J Clin Oncol"},{"issue":"16_Suppl.","key":"1211_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_SUPPL.TPS4197","volume":"42","author":"RK Kelley","year":"2024","unstructured":"Kelley RK, Cleary JM, Sahai V, Baretti M, Bridgewater JA, Hua Z, et al. A phase 1\/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of Ivosidenib in combination with Nivolumab and Ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma. J Clin Oncol. 2024;42(16_Suppl.):TPS4197. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.TPS4197.","journal-title":"J Clin Oncol"},{"key":"1211_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101171","volume":"50","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Khan S, Groot Koerkamp B, Roessler S, Andersen JB, Raggi C, et al. Mapping the landscape of biliary tract cancer in Europe: challenges and controversies. Lancet Reg Health Eur. 2025;50:101171. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101171.","journal-title":"Lancet Reg Health Eur"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01211-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:55:00Z","timestamp":1780131300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01211-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01211-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lena Dreikhausen, Alexander Olkus, Michael Dill, Christoph Springfeld, Philipp Heumann, Nadine Schulte, Konstantina Atanasova, Matthias P. Ebert, Anne Letsch, Anna M. Wandmacher, and Tianzuo Zhan have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval was granted by the Ethics Committee of Heidelberg University (identifier: 2022-823_1-AF 11) and approved by all participating centers. TriNetX utilizes aggregated de-identified patient records, and analysis of the TriNetX database does not require approval by the ethics committee. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Because of the retrospective design of the study, no written informed consent from patients was required, as decided by the local ethics board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Genomic data are provided in Table\n                      \n                      . Data used in this article may be made available upon reasonable request from the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LD, AMW, and TZ conceived and designed the study. LD, KA, AMW, and TZ analyzed the data. LD, AO, MTD, CS, PH, NS, MPE, AL, AMW, and TZ collected clinical data and provided critical data interpretation. LD, AMW, and TZ. wrote the manuscript. All authors have read and provided comments on the manuscript. All authors approved the manuscript and gave their consent for submission and publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}